209 天前 - … osimertinib was the preferred first-line option for advanced EGFR+ NSCLC (31,2 –
76,9%) in all countries, followed by gefitinib, erlotinib and afatinib. Upon disease progression …

212 天前 - … by 33% to 51% in the erlotinib, lapatinib, cytarabine, and gefitinib treated MA9
transgenic embryos (Figure 2). Treatment with these drugs did not significantly change the lyz …

213 天前 - … Patients were randomized 1:1 and received osimertinib 80 … (gefitinib 250 mg qd or
erlotinib 150 mg qd). Plasma was collected at baseline and multiple timepoints until treatment …

213 天前 - … months) were reported in patients treated with tepotinib plus gefitinib compared to …
gefitinib was more than 1 year in six patients (50.0%) and longer than 4 years in three patients…

216 天前 - … overall survival rates for gefitinib, erlotinib, afatinib and … The median time to
treatment failure of gefitinib, erlotinib, … The frequency of gefitinib and erlotinib use has decreased …

216 天前 - … We aimed to compare the acquired T790M acquisition rates after treatment with
different first-generation (gefitinib, erlotinib, and icotinib) and secondgeneration (afatinib and …

219 天前 - … In BM patients, gefitinib/erlotinib-treated ones with 19 deletion … NSCLC patients,
in which gefitinib/erlotinib-treated patients presented a shorter PFS compared to afatinib-treated …

220 天前 - … to tyrosine kinase pathway inhibitors (Erlotinib, Gefitinib, Afatinib), KRAS-… patients.
They can provide information for clinicians to establish timely strategies for cancer treatment. …

220 天前 - … ), gefitinib and erlotinib significantly improved the therapeutic effect in non–small
cell lung cancer (NSCLC) patients … promising EGFR TKI for the treatment of NSCLC patients. …

221 天前 - … Patients aged 18 years or older treated with EGFRis for lung cancer were included
in the exposed group. The EGFRi agents included gefitinib, erlotinib, … gefitinib and erlotinib. …